Form 4: Neumora Therapeutics Reprices Executive Stock Options, Lowering Exercise Price for Key Officer

Neumora Therapeutics, Inc. has repriced stock options for Chief Legal and Administrative Officer Jason Duncan and other key personnel, significantly reducing the exercise price to $0.72 per share from $1.69, following stockholder approval.

Summary

• Neumora Therapeutics, Inc. (NMRA) stockholders approved the repricing of outstanding stock options on May 28, 2025.
• The repricing affects options held by members of the Board, certain employees, and other service providers, including Chief Legal and Administrative Officer Jason Duncan.
• The exercise price for these options has been reduced from $1.69 per share to $0.72 per share.
• Jason Duncan's repriced options include 400,000 shares with a vesting commencement date of December 11, 2023, and 500,000 shares with a vesting commencement date of February 13, 2025.
• Vesting for both tranches occurs with 25% on the first anniversary of their respective vesting commencement dates, followed by 1/48th of the total shares vesting monthly thereafter, leading to full vesting on the fourth anniversary.
• The repricing is contingent on the Reporting Person remaining in service to the Issuer through August 13, 2026.

Sentiment

Score: 3

Explanation: The repricing of stock options, while beneficial for the recipient, generally signals poor past stock performance and can be viewed negatively by existing shareholders due to potential dilution and perceived misalignment of interests. This is a negative signal for the stock.

Positives

• The repricing makes the stock options more valuable and potentially exercisable for the Chief Legal and Administrative Officer, Jason Duncan, and other affected personnel, serving as a retention incentive.
• Stockholder approval indicates alignment between the company's leadership and its investors on this compensation strategy.

Negatives

• The significant reduction in exercise price from $1.69 to $0.72 per share suggests that the original options were likely "underwater" (i.e., the market price was below the exercise price), indicating poor stock performance since the original grant dates.
• Option repricing can be dilutive to existing shareholders if the options are exercised, and it can be perceived negatively as it benefits management at the expense of shareholder value.
• The repricing may signal a lack of confidence by management in the company's ability to achieve a stock price that would make the original options valuable.

Risks

• Shareholder Dilution: If the repriced options are exercised, it could lead to an increase in the number of outstanding shares, potentially diluting the ownership percentage of existing shareholders.
• Negative Investor Perception: Option repricing, especially when significant, can be viewed unfavorably by investors as it may suggest poor past performance or a misalignment of interests between management and shareholders.
• Retention Risk: The condition that the reporting person must remain in service through August 13, 2026, implies a risk of losing key personnel if this condition is not met or if the individual chooses to leave.

Future Outlook

The repricing of stock options is contingent on the Reporting Person remaining in service to the Issuer through August 13, 2026, indicating a strategic effort to retain key personnel for at least the next year.

Industry Context

Stock option repricing is a compensation strategy sometimes employed by biotechnology and pharmaceutical companies, particularly those with volatile stock performance or in early development stages, to retain key talent when original equity grants are underwater. This practice aims to re-incentivize executives and employees by making their equity awards valuable again, which is crucial in an industry heavily reliant on long-term R&D and talent retention.

Comparison to Industry Standards

• Option repricing is generally viewed with caution by corporate governance experts and institutional investors. While it can be a tool for retention, it often signals underperformance relative to initial expectations.
• Companies like Biogen or Gilead Sciences typically avoid such broad repricings unless under extreme pressure, as it can be seen as misaligned with shareholder interests.
• However, smaller, earlier-stage biotech firms, which often experience significant stock volatility, may resort to repricing more frequently than established industry giants to maintain competitive compensation packages.
• Without specific comparable repricing events from direct competitors, it's difficult to assess if the magnitude of this repricing ($1.69 to $0.72) is standard, but the act itself is less common among highly successful, stable companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to dilution and the signal of past stock underperformance.
• Employees/Executives: Positive impact as their stock options become more valuable, enhancing retention and motivation.

Next Steps

• Continued vesting of stock options for Jason Duncan and other personnel, contingent on continued service.
• Monitoring of Neumora Therapeutics' stock performance relative to the new exercise price.

Key Dates

Recommendation

Keywords

Neumora Therapeutics, NMRA, Stock Option Repricing, SEC Form 4, Executive Compensation, Jason Duncan, Beneficial Ownership, Equity Compensation, Corporate Governance, Insider Trading, Biotechnology, Pharmaceuticals